Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Top Cited Papers
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10285), 1637-1645
- https://doi.org/10.1016/s0140-6736(21)00676-0
Abstract
No abstract availableFunding Information
- National Institute for Health Research
- Medical Research Council
This publication has 29 references indexed in Scilit:
- The good and the bad: using C reactive protein to distinguish bacterial from non-bacterial infection among febrile patients in low-resource settingsBMJ Global Health, 2020
- Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyBMJ, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Estimates of the severity of coronavirus disease 2019: a model-based analysisThe Lancet Infectious Diseases, 2020
- Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-upJournal of Infection, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-α and interleukin-6 in patients with sepsisCritical Care Medicine, 1999